Diabetic Medications for CKD
For patients with type 2 diabetes and CKD with eGFR ≥30 mL/min/1.73 m², start both metformin AND an SGLT2 inhibitor as first-line therapy, then add a long-acting GLP-1 receptor agonist if additional glycemic control is needed. 1
First-Line Therapy Algorithm
eGFR ≥30 mL/min/1.73 m²
- Metformin + SGLT2 inhibitor (dual first-line therapy)
- Both medications provide kidney and cardiovascular protection beyond glucose control 1
- SGLT2 inhibitors can be initiated down to eGFR ≥20 mL/min/1.73 m² and continued until dialysis 1, 2
eGFR <30 mL/min/1.73 m²
- Stop metformin - do not initiate or continue 1
- Continue SGLT2 inhibitor if already started (can initiate if eGFR ≥20) 1
- Consider GLP-1 RA, DPP-4 inhibitor, or insulin for glycemic control 1
Metformin Dosing by eGFR
| eGFR Range | Action |
|---|---|
| ≥60 | Full dose - no adjustment needed |
| 45-59 | Continue same dose; consider reduction in certain conditions |
| 30-44 | Halve the dose |
| <30 | Stop metformin completely |
Starting dose: 500-850 mg once daily, titrate by 500 mg every 7 days 1
Critical monitoring:
- Check eGFR at least annually when ≥60, every 3-6 months when <60 1
- Monitor vitamin B12 after 4 years of use 1
Second-Line Therapy: GLP-1 Receptor Agonists
When to add: If glycemic targets not met with metformin + SGLT2i, or if either cannot be used 1
Preferred agents with cardiovascular benefits:
- Semaglutide (injection 0.5-1 mg weekly or oral 3-14 mg daily) - has demonstrated CKD benefits 2
- Dulaglutide (0.75-1.5 mg weekly)
- Liraglutide (1.2-1.8 mg daily)
GLP-1 RA Dosing in CKD
| Agent | eGFR Restriction |
|---|---|
| Dulaglutide | Use if >15 mL/min/1.73 m² |
| Semaglutide | No adjustment; limited data in severe CKD |
| Liraglutide | No adjustment; limited data in severe CKD |
| Exenatide ER | Use only if ≥45 mL/min/1.73 m² |
| Exenatide | Use only if CrCl >30 mL/min |
Start low, titrate slowly to minimize GI side effects 1
Additional Therapy Options (Third-Line)
When metformin + SGLT2i + GLP-1 RA are insufficient:
For all CKD stages (including eGFR <30 and dialysis):
- DPP-4 inhibitors (require dose adjustment)
- Insulin (increased hypoglycemia risk as eGFR declines)
For eGFR ≥30 only:
- Sulfonylureas (high hypoglycemia risk)
- TZDs (fluid retention risk)
- Alpha-glucosidase inhibitors
Critical Pitfalls to Avoid
Metformin lactic acidosis risk: Absolutely stop at eGFR <30; do not restart 1
SGLT2i initiation timing: Can start down to eGFR 20, but glucose-lowering effect diminishes below 45 2, 3
Hypoglycemia in advanced CKD: Risk dramatically increases with insulin and sulfonylureas as kidney function declines - requires close monitoring and dose reduction 2
Never combine GLP-1 RA with DPP-4 inhibitors - redundant mechanism 1
Contrast media procedures: Stop metformin on procedure day and 48 hours post-procedure if eGFR <60 4
Evidence Strength
The KDIGO 2022 guidelines 1 provide the strongest framework, with Level 1B recommendations for metformin (eGFR ≥30) and GLP-1 RA use. The dual first-line approach with metformin + SGLT2i represents a paradigm shift from traditional glucose-centric therapy to organ-protective treatment, supported by dedicated kidney outcome trials showing SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) slow CKD progression independent of glucose lowering 5, 6. Recent data on semaglutide extends cardiovascular and kidney benefits to GLP-1 RAs in this population 2.